Cisplatin
Platinol · Platinum agent
Proximal tubular ATN + magnesium wasting; the archetype.
ATNLYTEPRE
SevereOpen →
Bisphosphonate
Ibandronate
Boniva · Iband
The kidney-gentlest nitrogen bisphosphonate — renal events near placebo at standard doses.
MildNitrogen bisphosphonate · approved 2003
Metastatic bone disease (breast)Hypercalcemia of malignancyPost-menopausal osteoporosis
Signature kidney injury
Acute Tubular Necrosis
Lower renal risk than zoledronate or pamidronate. In a 2-year phase III breast-cancer trial, adverse renal events with IV ibandronate were ~4% versus ~4.5% with placebo — essentially at background. Bisphosphonates as a class can cause toxic ATN (zoledronate) or collapsing FSGS (pamidronate), but ibandronate is the renal-safety outlier within the class.
Source: Jackson, Oncologist 2005 (renal AEs 4% vs 4.5% placebo — attributable nephrotoxicity ≈ 0)
Mechanism of kidney injury
Bisphosphonates are filtered, not metabolized, and concentrate in the renal cortex; ~50–60% of an IV dose is renally excreted while the remainder binds bone. High peak tubular concentrations — driven by dose and infusion rate — produce dose-dependent toxic acute tubular necrosis of the proximal tubule (the zoledronate pattern), whereas slow pamidronate accumulation more often injures podocytes (collapsing FSGS). Ibandronate has high bone-binding avidity (~98% bone uptake even in dialysis patients) and is given at lower molar doses over recommended infusion times, so nephrotoxic tubular peaks are rarely reached and clinically significant injury is uncommon.
Clinical presentation
Usually no significant change in serum creatinine at standard dosing. When injury occurs it is a non-oliguric creatinine rise with bland or granular-cast urine consistent with ATN, sometimes accompanied by hypocalcemia, hypophosphatemia or hypomagnesemia from the antiresorptive effect.
Onset
Acute when it occurs (days), related to dose and infusion rate; antiresorptive electrolyte effects within the first days.
Reversibility
Reversible
Anticancer mechanism
Nitrogen-containing bisphosphonate that inhibits farnesyl pyrophosphate synthase in the mevalonate pathway of osteoclasts, disrupting prenylation of small GTPases (Ras/Rho/Rac), impairing osteoclast cytoskeleton and survival and thereby suppressing bone resorption. Used for malignancy-associated bone disease, hypercalcemia of malignancy and post-menopausal osteoporosis.
Management
Withhold for renal-function decline, hydrate, and provide supportive care; injury is typically reversible. Correct co-existing hypocalcemia/hypophosphatemia. No specific antidote.
Risk factors
- High or rapidly infused IV dose
- Pre-existing CKD
- Volume depletion
- Concurrent nephrotoxins (NSAIDs, aminoglycosides, contrast)
Prevention
- Adequate hydration before/after infusion
- Adhere to recommended infusion times
- Check creatinine before each dose
- Dose-reduce or withhold in renal impairment per label
Note · Among IV bisphosphonates, ibandronate carries the most favorable renal-safety label; absolute incidence near placebo at standard doses. In ESKD, high bone avidity means a 2 mg IV dose binds bone equivalently to 4–5 mg in normal renal function.
Clinical depth
Renal dose adjustment
Oral/IV for osteoporosis: no adjustment for CrCl ≥30 mL/min; not recommended (or use with caution) below 30 mL/min. Oncology IV dosing should be reduced and infused slowly in renal impairment; withhold for acute decline in renal function and reassess.
Dialyzability & ESKD dosing
Negligible plasma drug at steady state due to rapid bone uptake; not meaningfully dialyzed. In hemodialysis patients a reduced IV dose (e.g., 2 mg) given after dialysis achieves equivalent bone binding (Bergner 2005).
Differential diagnosis
Distinguish drug-related ATN from hypercalcemia-of-malignancy pre-renal AKI (which the bisphosphonate is treating) and from contrast or NSAID injury; collapsing FSGS with heavy proteinuria points to pamidronate rather than ibandronate.
Monitoring
- Serum creatinine before each IV dose
- Serum calcium, phosphate and magnesium periodically
- Volume/hydration status around infusion
- 25-OH vitamin D (replete before starting to avoid hypocalcemia)
Key trials & series
- The Jackson Oncologist 2005 renal-safety pooled analysis (~4% vs ~4.5% placebo)
- Markowitz Kidney Int 2003 zoledronate toxic-ATN series (class comparator)
Clinical pearls
- Ibandronate is the bisphosphonate to choose when renal safety is paramount — its renal-event rate sits at placebo level.
- Tubular peak concentration (dose ÷ infusion time), not cumulative dose, drives bisphosphonate ATN — never shorten the infusion.
- In ESKD, exploit high bone avidity: a 2 mg dose binds bone like 4–5 mg in normal kidneys, so dose down.
- Replete vitamin D and watch calcium — antiresorptive hypocalcemia is the more common 'electrolyte' event than any tubular injury.
Where it strikes
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Acute Tubular NecrosisElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of bisphosphonates.
Musculoskeletal
Myalgia, myositis, rhabdomyolysis, ONJ
- Osteonecrosis of the jaw, hypocalcemia, acute-phase reaction
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
PMIDRenal safety of ibandronate.Jackson GH et al. · Oncologist 2005 · PMID 16264108Reports adverse renal events ~4% vs ~4.5% placebo over 2 years; basis for the favorable renal label.LandmarkBisphosphonate nephrotoxicity.Perazella MA et al. · Kidney Int 2008 · PMID 18685574Authoritative review: toxic ATN with zoledronate, collapsing FSGS with pamidronate, and the comparatively safe renal profile of ibandronate.PMIDToxic acute tubular necrosis following treatment with zoledronate (Zometa).Markowitz GS et al. · Kidney Int 2003 · PMID 12787420Defines the class pattern of bisphosphonate-induced toxic ATN against which ibandronate's lower risk is judged.PMIDNephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.Bergner R et al. · Pharmacol Res 2015 · PMID 25976681Experimental comparison showing lower ibandronate tubular toxicity, including an impaired-renal-function model.PMIDHigh bone-binding capacity of ibandronate in hemodialysis patients.Bergner R et al. · Int J Clin Pharmacol Res 2005 · PMID 16366420Shows ~98% bone uptake and minimal plasma drug in ESKD; supports reduced post-dialysis dosing.PMIDIs there a role for bisphosphonates in vascular calcification in chronic kidney disease?Hildebrand S et al. · Bone 2020 · PMID 33188959Reviews bisphosphonate pharmacokinetics, bioavailability and skeletal effects across declining GFR, including ibandronate.